SOLICITATION NOTICE
A -- Production of Modified Dendrimer Nanoparticle (MDNP) Virus Vaccine Against Alphaviral Infection
- Notice Date
- 3/20/2017
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH17R0004
- Archive Date
- 4/19/2017
- Point of Contact
- Samantha L. Connors, Phone: 3016196979
- E-Mail Address
-
samantha.l.connors.civ@mail.mil
(samantha.l.connors.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- The U.S. Army Medical Research Acquisition Activity (USAMRAA), 820 Chandler Street, Fort Detrick, Maryland, 21702, intends to award a sole source contract to the Massachusetts Institute of Technology (MIT) for production of Modified Dendrimer Nanoparticle virus vaccine (MDNP) against Alphaviral infection for the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID). The proposed contract action is for services for which the Government intends to solicit and negotiate with only one source under the authority at FAR 6.302-1. USAMRIID has a requirement for production of Modified Dendrimer Nanoparticle virus vaccine (MDNP) against Alphaviral infection. The services to be provided will enable USAMRIID to identify candidate MDNP Vaccines for Venezuelan equine encephalitis (VEE) and other alphaviruses. The support includes production of replicon vectors, testing for in-vitro expression, synthesis and characterization of MDNP candidates, and control vaccine formulation. These services are in support of a USAMRIID program funded by the Defense Threat Reduction Agency (DTRA) to evaluate strategies to inmprove Alphaviral vaccines by rapid generation of modified dendrimer nanaparticles. The anticipated period of performance is one 12-month base period and four 12-month option periods. MIT is uniquely qualified to provide the required services, which were developed from an existing collaboration between USAMRIID and MIT to develop a synthetic rapid production vaccine platform aimed to fill specific Department of Defense (DoD) technology gaps. The vaccine platform developed is a fully synthetic RNA-based platform composed of Modified Dendrimer Nanoparticles (MDNP) and programmable replicon mRNAs which allow for efficient delivery and protection against RNA proteases. MIT has illustrated that a MDNP-delivered replicon RNA encoding the hemagglutinin protein (HA) of an H1N1 influenza virus (A/WSN/33) or the Ebola virus (EBOV) glycoprotein (GP) protects mice against lethal viral infection. Currently, MIT has an ongoing effort focused on the application of DNA and RNA delivery systems in vitro and in vivo. Furthermore, MIT has the expertise to optimize and deploy the MDNP technology for vaccination purposes against Alphaviral infection. An RFP will be issued to the Massachusetts Institute of Technology on a sole source basis. The North American Industry Classification System (NAICS) code for this requirement is 541712 and the small business size standard is 1,000 employees. Any sources that believe they are eligible to provide these services must respond to this notice in writing. Responses must be supported with clear and convincing evidence which articulates the ability to perform the services outlined above. A request for documentation will not be considered an affirmative response. Information received will be considered solely for the purposes of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, which reflects fifteen (15) days after the publication of this notice, the contract will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Samantha L. Connors at SAMANTHA.L.CONNORS.CIV@MAIL.MIL. Interested concerns must identify their capability to the above email address no later than 11:59 PM Eastern Time, 04 April 2017.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH17R0004/listing.html)
- Record
- SN04441093-W 20170322/170320234717-1edddbbfaf1f93e330828760fed08247 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |